TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with...
SK bioscience was selected to lead the Gates Foundation-funded ROTOR project, establishing a global collaboration framework. SK bioscience, PATH, Slal...
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell...
Following encouraging earlier-phase clinical data, the Company is advancing its acne trial ahead of schedule while maintaining atopic dermatitis global P...
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming imm...
Phase I results provide platform-level validation supporting AdJane's broader development programs in pandemic preparedness, respiratory infectious disea...
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thal...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), me...
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statist...
Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announ...
© 2026 Biopharma Boardroom. All Rights Reserved.
